Association between p53 and human papillomavirus in head and neck cancer survival

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 2, 2008, Pages 421-427

  Smith, Elaine M ^a,d   Wang, Donghong ^a,b   Rubenstein, Linda M ^a   Morris, William A ^a   Turek, Lubomir P ^b,c   Haugen, Thomas H ^b,c  

^a Department of Epidemiology   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HEAD AND NECK CANCER; HUMAN; HYPOPHARYNX CANCER; LARYNX CANCER; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; OROPHARYNX CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; WART VIRUS;

FEMALE; HEAD AND NECK NEOPLASMS; HUMAN PAPILLOMAVIRUS 16; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 39449129494     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-2597     Document Type: Article

References (40)

1. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10.
2. Gasco M, Crook T. The p53 network in head and neck cancer. Oral Oncol 2003;39:222-31.
3. Geisler SA, Olshan AF, Weissler MC, et al. P16 and p53 protein expression as prognostic indicators of survival and disease recurrence from head and neck cancer. Clin Cancer Res 2002;8:3445-53.
4. Taylor D, Koch WM, Zahurak M, Shah K, Sidransky D, Westra WH. Immunohistochemical detection of p53 protein accumulation in head and neck cancer: correlation with p53 gene alterations. Hum Pathol 1999;30:1221-5.
5. Shin DM, Lee JS, Lippman SM, et al. p53 expressions: predicting recurrence and second primary tumors in head and neck squamous cell carcinoma. J Natl Cancer Inst 1996;88:519-29.
6. Brennan JA, Boyle JO, Koch WM, et al. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. N Engl J Med 1995;332:712-7.
7. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000;92:709-20.
8. Koch WM, Lango M, Sewell D, Zahurak M, Sidransky D. Head and neck cancer in nonsmokers: a distinct clinical and molecular entity. Laryngoscope 1999;109:1544-51.
9. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH. Onyx-015, an E1b gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997;3:639-45.
10. Smith EM, Hoffman HT, Summersgill KS, Kirchner HL, Turek LP, Haugen TH. Human papillomavirus risk of oral cancer. Laryngoscope 1998;108:1098-103.
11. Smith EM, Ritchie JM, Summersgill KF, et al. Human papillomavirus in oral exfoliated cells and risk of head and neck cancer. J Natl Cancer Inst 2004;96:449-55.
12. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005;14:467-75.
13. Pinheiro NA, Villa LL. Lowfrequency of p53 mutations in cervical carcinomas among Brazilian women. Brazilian J Med Biol Res 2001;34:727-33.
14. Tommasino M, Accardi R, Caldeira S, et al. The role of TP53 in cervical carcinogenesis. Hum Mutat 2003;21:307-12.
15. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990;63:1129-36.
16. NCI SEER. Available from: http://seer.cancer.gov/csr/1973-1999, 2002, 2004.
17. Riethdorf S, Friedrich RE, Ostwald C, et al. p53 gene mutations and HPV infection in primary head and neck squamous cell carcinomas do not correlate with overall survival: a long-term follow-up study. J Oral Pathol Med 1997;26:315-21.
18. Pintos J, Franco EL, Black MJ, Bergeron J, Arella M. Human papillomavirus and prognoses of patients with cancers of the upper aerodigestive tract. Cancer 1999;85:1903-9.
19. Kyzas PA, Loizou KT, Ioannidis JP. Selective reporting biases in cancer prognostic factor studies. J Natl Cancer Inst 2005;97:1043-55.
20. Couture C, Raybaud-Diogene H, Tetu B, et al. p53 and Ki-67 as markers of radioresistance in head and neck carcinoma. Cancer 2002;94:713-22.
21. Ritchie JM, Smith EM, Summersgill KF, et al. Human papillomavirus infection as a prognostic factor in carcinomas of the oral cavity and oropharynx. Int J Cancer 2003;104:336-44.
22. Fleming ID, Cooper JS, Henson DE, et al. AJCC cancer staging manual. 5th ed. Philadelphia (PA): Lippincott-Raven; 1997.
23. Emmert-Buck MR, Bonner RF, Smith PD, et al. Laser capture microdissection. Science 1996;274:998-1001.
24. National Death Index. Available from: http://www.cdc.gov/nchs/r&d/ ndi/ndi.htm.
25. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
26. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
27. S-Plus 6.2 Academic Site Ed. Seattle (WA): Math Soft, Inc.; 2003.
28. Cox DR. Regression models and life tables. JR Stat Soc B 1972;34:187-220.
29. Allison PD. Survival analysis using the SAS system: a pratical guide. Cary (NC): SAS Institute, Inc.; 1995.
30. SAS System for Windows v91. Cary (NC): SAS Institute; 2003.
31. Schwartz SR, Yueh B, McDougall JK, Daling JR, Schwartz SM. Human papillomavirus infection and survival in oral squamous cell cancer: a population-based study. Otolaryngol Head Neck Surg 2001;125:1-9.
32. Haraf DJ, Nodzenski E, Brachman D, et al. Human papilloma virus and p53 in head and neck cancer: clinical correlates and survival. Clin Cancer Res 1996;2:755-62.
33. Mao EJ, Schwartz SM, Daling JR, Oda D, Tickman L, Beckmann AM. Human papilloma viruses and p53 mutations in normal premalignant and malignant oral epithelia. Int J Cancer 1996;69:152-8.
34. Pruneri G, Pignataro L, Carboni N, et al. Clinical relevance of p53 and bcl-2 protein over-expression in laryngeal squamous-cell carcinoma. Int J Cancer 1998;79:263-8.
35. Mellin H, Friesland S, Lewensohn R, Dalianis T, Munck-Wikland E. Human papillomavirus (HPV) DNA in tonsillar cancer: clinical correlates, risk of relapse, and survival. Int J Cancer 2000;89:300-4.
36. Cabelguenne A, Blons H, de Waziers I, et al. p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. J Clin Oncol 2000;18:1465-73.
37. Scheffner M, Takahashi T, Huibregtse JM, Minna JD, Howley PM. Interaction of the human papillomavirus type 16 E6 oncoprotein with wild-type and mutant human p53 proteins. J Virol 1992;66:5100-5.
38. Sherr CJ, McCormick F. The Rb and p53 pathways in cancer. Cancer Cell 2002;2:103-12.
39. Temam S, Flahault A, Perie S, et al. p53 gene status as a predictor of tumor response to induction chemotherapy of patients with locoregionally advanced squamous cell carcinomas of the head and neck. J Clin Oncol 2000;18:385-94.
40. Perrone F, Suardi S, Pastore E, et al. Molecular and cytogenic subgroups of oropharyngeal squamous cell carcinoma. Clin Cancer Res 2006;12:6643-51.